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Abstract
Background: As part of the NHS desire to move services closer to where people live, and provide greater
accessibility and convenience to patients, Brighton and Hove Clinical Commissioning Group (CCG) underwent a
review of their anticoagulation services during 2008. The outcome was to shift the initiation and monitoring service
in secondary care for non-complex patients, including domiciliary patients, into the community. This was achieved
via a procurement process in 2008 resulting in the Community Pharmacy Anticoagulation Management Service
(CPAMs) managed by Boots UK (a large chain of community pharmacies across the United Kingdom).
Methods: This evaluation aims to review the outcomes (International Normalised Ratio [INR] readings) and experiences
of those patients attending the anticoagulation monitoring service provided by community pharmacists in Brighton and
Hove. All patients on warfarin are given a target INR range they need to achieve; dosing of and frequency of appointment
are dependent on the INR result. Outcome measures for patients on the CPAM service included percentage INR readings
that were within target range and the percentage time the patient was within therapeutic range. Data collected from
2009 to 2016 were analysed and results compared to the service targets. Patient experience of the service was evaluated
via a locally developed questionnaire that was issued to patients annually in the pharmacy.
Results: The evaluation shows that community pharmacy managed anticoagulation services can achieve outcomes at a
level consistently exceeding national and local targets for both percentage INR readings in therapeutic target range (65.
4%) compared to the recommended minimum therapeutic target range of 60.0% and percentage time in therapeutic
range (72.5%, CI 71.9–73.1%) compared to the national target of 70.0%. Patients also indicated they were satisfied with
the service, with over 98.6% patients rating the service as good, very good or excellent.
Conclusion: The Brighton and Hove CPAM service achieved above average national target management of INR and
positive patient feedback, demonstrating that community pharmacy is ideally placed to provide this service safely and
deliver enhanced clinical outcomes and positive patient experience.
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Background
Warfarin is the most commonly prescribed oral anti-
coagulant in the UK [1] and is used in the clinical man-
agement of a variety of conditions including atrial
fibrillation (AF), post-myocardial infarction, heart valve
replacement and deep vein thrombosis (DVT). A num-
ber of recognised side effects are associated with
warfarin use, from nausea, vomiting and minor bleeding
to more serious side effects such as major bleeding and
warfarin-induced skin necrosis [2]. Such side effects have
been identified as a causal agent in 10% of all admissions
for adverse drug reactions [3].
Experience of side effects of warfarin use are related to
a patient’s International Normalised Ratio (INR) level, a
measure of the delay in blood clotting caused by war-
farin. A supra-therapeutic INR can put patients at risk
of bleeding, while prophylaxis against thromboembolic
events may not be achieved with a sub-therapeutic range
[4]. The specific recommended target range of INR
values depends upon the disease and clinical condition.
The aim of an anticoagulant monitoring service is to
stabilise the INR within recommended targets for the clin-
ical indication being managed while maximising effective
treatment. These targets include percentage of readings
that are within therapeutic range (RR) and the percentage
time the patient is within therapeutic range (TTR).
The majority of anticoagulation monitoring currently
takes place within secondary care (both hospital in- and
out-patient settings). However, delivery of these services
within secondary care faces a number of challenges
which include an increase in numbers of older patients,
clinical indications for warfarin and the accessibility of a
centralised clinic setting supporting a wide geography.
These challenges have been reiterated more generally in
the National Health Service (NHS) 5 Year Forward View
which highlights the efficiency savings the NHS must
make and the push for moving more services from sec-
ondary care into the community [5]. The White Paper
‘Our Health, Our Care, Our Say’ (2006) highlighted how
health and social care services needed to be closer to
communities providing a flexible tailored service giving
patients more control over their treatment [6]. Part of
the English Government’s intent is to move clinical ser-
vices, such as anticoagulation clinics, into the commu-
nity to improve access and operational capacity within
the local health economy [6]. Since the publication of
these papers, more anticoagulation clinics are now
within the community in places such as general practices
(where a clinic may be run by a nurse or pharmacist),
within community pharmacies, or at patient’s homes
with the use of self-testing.
Other countries have already experienced some success
with providing anticoagulation monitoring through com-
munity pharmacy, for example the Community Pharmacy-
Based Anticoagulation Management Service in New
Zealand [7] and other pilots in Canada and the US [8–10].
Whilst some pharmacy-run clinics have been in place since
1979 [11], there has been limited access to primary
provision of anticoagulation in the UK until recent years. In
recognition that this is a complex area for planning and
commissioning, the National Institute for Health and Care
Excellence (NICE) has developed a Commissioning Guide
to support the NHS to commission high quality, evidence
based anticoagulant services with the potential to change
local care pathways [12]. This has impacted on where such
services are provided; in secondary or community care.
The development of anticoagulation clinics led by
pharmacists could significantly increase patient access to
professional advice and testing, leading to improved INR
control and self-care [13]. Pharmacists are well placed to
take on the role of practitioner in this field as their
knowledge of drug interactions, pharmaceutical prod-
ucts, pharmacokinetic principles and counselling skills
enables them to effectively manage patients safely within
agreed treatment protocols.
In 2008 Boots UK was awarded the NHS local contract
to operate a community pharmacy led service in the
Brighton and Hove area of England. The Community
Pharmacy Anticoagulation Management (CPAM) service
was implemented in 17 pharmacies (nine Boots UK, and
eight independently owned pharmacies) across the local-
ity in October 2009, with a mixture of pharmacies of
different sizes and locations (e.g. local, high street, large
city centre). The aim of this service evaluation was to
compare outcomes achieved locally to recommended
targets for percentage RR and percentage TTR, and as-
sess levels of patient satisfaction.
Methods
Boots UK has managed the CPAM service since 2009.
Other pharmacy providers continue to be subcontracted
to ensure good geographical coverage. ‘Here’, formally
Brighton and Hove Integrated Care Services Ltd., was
engaged to manage patient referral and escalation of
clinical queries to general practitioners (GPs) with a spe-
cial interest in anticoagulation treatment. The CPAM
contract stipulated the provision of access to GPs with
specialist interest to provide advice to the pharmacists
through electronic communication via the DAWN® AC
Anticoagulation software version seven (4S Information
Systems Ltd., Cumbria, UK). The service was commis-
sioned to transfer and maintain existing noncomplex pa-
tients prescribed warfarin in secondary care within
Brighton and Hove to clinics run on the pharmacy
premises or via a domiciliary service. Patients were eli-
gible for referral if they had at least two out of their last
four readings in target range, and did not fall into the
exclusion criteria (under 16 years; newly diagnosed with
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venous thromboembolism (VTE); VTE patients still on
low molecular weight heparin; pregnant; antiphsopholi-
pid syndrome). Initially, patients in the maintenance
phase of treatment were chosen by secondary care clini-
cians using their clinical judgement; most patients had
AF and were deemed to be stable by these clinicians
having already completed the initiation period (usually
6 weeks from the start of treatment), these were consid-
ered to be ‘noncomplex’ patients. Noncomplex patients
are also able to attend a community clinic for initiation
of warfarin treatment to agreed protocols on referral
from their doctor. Competencies for the service are in
line with Brighton and Sussex University Hospital NHS
Trust guidelines which are also in line with national rec-
ommendations provided by the National Patient Safety
Agency (NPSA) [14].
Within Boots, a team of seven pharmacists who had
completed consultation skills training and were assessed
by the clinical lead as being competent to clearly com-
municate with patients on dosing and other relevant
clinical discussions, were recruited to provide the service
across eight pharmacies. In addition, independent phar-
macies each identified a pharmacist to provide the ser-
vice. A Boots pharmacist independent prescriber (a
pharmacist accredited by the General Pharmaceutical
Council to prescribe autonomously for any condition
within their clinical competence) with specialist interest
in anticoagulation was appointed as Lead Clinical
Pharmacist for the service. All pharmacists attended the
National Centre for Anticoagulation Training at the
University of Birmingham and completed a three day
training course and final examination in oral anticoagu-
lation management. A one-day local training course was
also provided to all pharmacists covering service proce-
dures, finger prick sampling technique, use of the point
of care testing meter and the software systems. Each
pharmacist observed the Lead Clinical Pharmacist treat-
ing ten patients, and was then observed themselves
treating ten patients before final competency sign-off.
Pharmacist competence was reviewed six-monthly via
auditing of the service data and annually by observation
of clinical practise by the Lead Clinical Pharmacist to
ensure standards were maintained.
At each clinic appointment a patient’s INR was mea-
sured by taking a capillary blood sample using a finger
prick device from the CoaguChek® XS Plus meter kit
(Roche, Basel, Switzerland) and analysed using the same
device. The INR result was input to an IT web based
software solution, DAWN® AC Anticoagulation software,
which provided pharmacists with support on dosing and
recall interval decisions. The system also provides an
appointment book which can track patients and ensure
follow up appointments are audited and actioned, as well
as providing the pharmacists with detailed patient
anticoagulation history and warfarin dosing algorithms.
The patient recall interval for appointments was based
on previous work by Ryan et al. [15]. At the end of each
appointment details of patient’s INR results and time
and date of their next appointment were conveyed ver-
bally to ensure patient understanding and recorded in
the patient’s information book to act as a reminder
(‘yellow book’ provided by the NPSA). The target INR
range for each patient was specified by the referring clin-
ician and double checked by the pharmacist against rec-
ommended targets for each indication.
Data on the percentage RR (total number of readings
within range divided by total number of visits) and aver-
age TTR for the service were extracted from the
DAWN® AC database from October 2009 to September
2016. The Rosendaal method was used to calculate the
percentage TTR for each patient [16]. This method cal-
culates INR-specific person time by incorporating the
frequency of INR measurements and their actual values
while assuming that changes between consecutive INR
measurements are linear over time. Data analysis was
undertaken on the maintenance period of treatment, this
excluded readings taken in the 6 week initiation period
(unless otherwise stated).
Level of patient satisfaction with the service was mea-
sured by undertaking an annual patient survey using a
questionnaire comprised of 14 questions. This was de-
veloped locally with NHS Brighton and Hove CCG and
was based on other current local service questionnaires.
In 2013 the questionnaire was amended to include the
NHS friends and family test question which are an-
swered on a five-point Likert scale [17]. The survey was
carried out annually over an eight-week period from
2011. Patients accessing the service in this time were
given a questionnaire and freepost envelope to allow
completion at a convenient time. Implied patient
consent was taken by return of the questionnaire and all
data were anonymised.
Data extracted from Dawn® AC Anticoagulation soft-
ware were analysed using Windows Excel 2013. Data
from completed questionnaires was analysed using SPSS
Version 22.
Results
A total of 2341 patients were included in data analysis
from October 2009 to June 2016. Due to the nature of
this continuing service, patients were transferred out of
the service (e.g. back to secondary care) or died, and
new patients also joined the service throughout the
evaluation period (see Fig. 1). Overall, a slightly higher
proportion of patients were male (1293, 56.0%) and the
majority of patients were white (2280, 97.6%; Table 1).
Patients ranged from 22 to 106 years of age (as of Sep-
tember 2016 when data were extracted); most tending to
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be older, with 89.7% of patients aged 61 years or over
(Table 1).
During the maintenance period (> 6 weeks treatment)
a total of 168,316 INR readings were recorded over the
evaluation period for 2341 patients. The average per-
centage RR for these patients, was 65.4% (Table 2).
During the maintenance period, the average TTR for all
patients was 72.5% (CI 71.9–73.1%, Table 2). The ana-
lysis demonstrate a slight decline in both metrics over
the evaluation period (see Additional file 1: Figure A1).
Any readings relating to the first quarter of a patient
joining the service (including initiation period, ‘initial’)
were compared with all readings which were not in the
first quarter of joining (‘subsequent’). On average, the
percentage TTR was higher for the ‘subsequent’ readings
than the ‘initial’ readings (68.4% [CI 67.4–69.4] vs 37.8%
[CI 32.2–43.4], p < 0.0001). This was also seen to be the
case for percentage RR (64.4% ‘subsequent’ vs 46.8% for
‘initial’, p < 0.0001). A comparison was made between
existing patients and those who left the service (defined
as missing data in any subsequent quarterly period). This
comparison suggests that patients who left the service
had significantly lower readings for both metrics, than
those who remained in the service (Table 2).
The DAWN® software is also used by other providers
of anticoagulation services across the UK (primary, com-
munity and secondary care), and comparison data were
obtained from the software provider for all other users
over a 6 month period leading to April 2016 (81 pro-
viders compared). Figure 2 shows that the Brighton and
Hove CPAM service achieved above average outcomes
for TTR and appears in the top 15 of providers.
A total of 2126 patients were surveyed about the ser-
vice (401 patients after the first year [2011], 772 after
the second year [2012] and 953 after the third year
[2013]). The majority of respondents were male (56.4%),
white (95.6%) and over 66 years old (80.2%). Overall sat-
isfaction with the service was very high; this can be seen
in Table 3.
Patient ratings of pharmacist interpersonal and com-
munication skills were very high (Table 4). Ratings for
information provided, however, were less positive (Table
4). In particular 13.0% (n = 267) of patients said that
they wanted more information about why they were tak-
ing warfarin, 31.0% (n = 347) said they wanted more on
side-effects and a further 2.8% (n = 31) patients said that
they received no information about side-effects at all.
The majority of patients found the pharmacy to be clean
and tidy (85.4%) and the consultation room to be suit-
able (95.1%); 13.5% of patients reported some problems
in contacting the pharmacy by phone.
Discussion
The evaluation has demonstrated that a community
pharmacy managed anticoagulation service can achieve
clinical outcomes at a level consistently exceeding tar-
gets; for percentage RR (65.4%) compared to the locally
Fig. 1 Turnover of patients over the course of the evaluation period.
Bars show the loss of patients (‘left’) and the addition of ‘new’
patients by quarter
Table 1 Demographics of patients in the CPAM service (data were
missing for some patients, percentages refer to known patients)
Patients
Number Percent
Gender (n = 2310) Female 1017 44.0%
Male 1293 56.0%
Ethnicity (n = 2337) White 2280 97.6%
Other 22 0.9%
Asian 13 0.6%
Black 9 0.4%
Indian 6 0.3%
Chinese 5 0.2%
Bangladeshi 1 0.0%
Pakistani 1 0.0%
Age group, in years
(n = 2341)
21–30 12 0.5%
31–40 27 1.2%
41–50 68 2.9%
51–60 134 5.7%
61–70 332 14.2%
71–80 615 26.3%
81–90 879 37.5%
≥91 274 11.7%
Table 2 Comparison of percentage TTR and RR for existing
patients versus patients who have left the service
Existing
(n = 1169)
Left
(n = 1172)
P value All patients
(n = 2341)
TTR % (CI) 78.0
(77.4–78.7%)
67.0
(66.1–68.0%)
p < 0.0001 72.5
(71.9–73.1%)
RR % 69.3% 61.4% p < 0.0001 65.4
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recommended minimum target of 60% and TTR (72.5%)
compared to the national target of 70% [18, 19]. The ini-
tial patients transferred to the community service from
the local NHS Trust were stable patients being pre-
scribed warfarin for AF. As the number of patients
transferred increased, so did the complexity of clinical
conditions to further include initiation of warfarin treat-
ment and those currently prescribed warfarin to manage
DVT risk, pulmonary embolism risk, heart-valve disease
and replacement heart valve management. It is already
recognised that TTR tends to be lower in the first few
months for newly warfarinised patients and our results
support this. Coupled with the results, this suggests that
patients joining the service tend to be less well main-
tained initially, this may explain the gradual reduction in
the percentages reported for both measures although
still consistently above NICE targets. This is reinforced
by the DAWN® AC benchmarking data reporting the
performance of all UK sites over a 6 month period in-
cluding all sites within both primary and secondary care
settings using the DAWN® AC dosing decision system.
Although the patient populations may differ across these
sites and so are not directly comparable, the
benchmarking data suggest that the Brighton and Hove
site is still performing well in comparison to other sites
providing a similar service in UK. This evaluation sup-
ports previous studies which have shown that commu-
nity pharmacy based anticoagulation clinics can be safe
and clinically effective [20, 21].
Patients’ overall satisfaction for the service over the 3
years of data was very high, with feedback consistently
rating above 98% at a minimum of ‘good’ whilst showing
67% rating the service as excellent. This mirrors other
studies which have looked at community based clinical
services [20, 21]. However, the findings show there is
still an opportunity to provide more information to
Fig. 2 Comparative data between CPAM site (filled black column) and all other UK sites using DAWN®. Bars show the percentage TTR (obtained
from DAWN® software providers) for the 6 months leading to April 2016 for each provider. The average TTR (71.5%) across all providers is shown
as a solid horizontal line
Table 3 Frequency of patients’ overall ratings of the service
(missing data, n = 43)
Patients ratings
Response n %
Very poor 2 0.1%
Poor 7 0.3%
Fair 21 1.0%
Good 112 5.4%
Very good 541 26.0%
Excellent 1400 67.2%
Total 2083 100%
Table 4 Percentage of positive ratings of pharmacists’
communication and interpersonal skills and information
provided. Patient group size varies as some questions were not
included in all 3 years of surveying patients and questions were
non-compulsory
Positive ratings
by patients
n %
Interpersonal and communication skills
Listen carefully (n = 2060) 2048 99.4%
Time to discuss problems (n = 1937) 1930 99.6%
Answered questionsa (n = 1848) 1840 99.6%
Confidence and trust (n = 2087) 2086 99.9%
Respect and dignity (n = 2085) 2083 99.9%
Information
Reason for taking warfarin (n = 2047) 1608 75.6%
Side-effects (n = 1119) 706 63.1%
Dose adjustment explaineda (n = 1780) 1772 99.6%
Use of the medicine (n = 1133) 933 82.3%
Referral to hospital - when & whya (n = 183) 173 94.5%
aWhere applicable
Ingram et al. BMC Health Services Research  (2018) 18:91 Page 5 of 7
patients including discussing potential side effects which
will continue to improve patient understanding and risk
management of potential adverse events.
There are a number of limitations of this work, which
impact the interpretation of the data. An example is the
limited nature of the data collected. As the analysis is
based on a simple audit, the reason for patients leaving
the service and patient comorbidities and indications
were not captured in the dataset. This means that it is
not possible to comment on how many left due to death,
treatment ending or switching to another treatment
option or other such reasons; or whether there are any
differences in warfarin management by indication. In fu-
ture work, capturing these elements would provide valu-
able additional insights when evaluating the service. The
survey data was collected anonymously which means that
it is possible that the same patient may have responded to
the survey in multiple years. Although this should be con-
sidered when interpreting the data, the patient’s overall
rating of the service did not change greatly from year to
year. In addition, the number of surveys handed out was
not recorded, therefore unfortunately it is not possible to
report on the response rate to the survey. As this was a
simple audit and no data were available on patient co-
morbidities etc., no analysis has been undertaken to ac-
count for risk-adjustment in the service population, or on
the populations of the other providers, which should be
taken into account when interpreting Fig. 2.
Anticoagulation management continues to evolve
rapidly and developing expertise within this clinical area
has also enabled the service to adapt in line with these
changes. Whilst Any Qualified Provider (AQP) is a
mechanism to commission such services, sole provider
models are also popular, if the appropriate access to pa-
tients can be assured, allowing less contract manage-
ment time for commissioners and an overview of the
results of whole population outcomes. Further innova-
tions on service delivery are currently being explored
including piloting a model for patient self-testing; pa-
tients utilise their own CoaguChek Plus meters following
an assessment by the anticoagulation pharmacist, and
discuss results and dosing. Another potential proposal is
the transition of the initiation clinic from a warfarin only
service, to include a detailed discussion around the
choice of a direct oral anticoagulant or warfarin in line
with NICE clinical guidance CG180 [22]. Indeed, the
slight decline in service users over the course of the ana-
lysis (Fig. 1), may be due to the increasing numbers of
patients prescribed these new alternatives to warfarin
treatment. This model utilises Independent Prescribers
to initiate the first prescriptions, thereby reducing refer-
ral into secondary care. Both service innovations allow
better access and choice for patients on anticoagulants
and support patient empowerment, thus demonstrating
that community pharmacy is able to adapt and meet the
changing needs of patients.
Conclusion
This evaluation has shown that community pharmacy is
ideally positioned to support the commissioning of key
services from primary care providing good clinical out-
comes whilst attaining high patient satisfaction for the
level of service and skills of the pharmacy team involved.
Additional file
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evaluation. (DOCX 24 kb)
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